Barclays PLC Has $825,000 Position in Certara, Inc. (NASDAQ:CERT)

Barclays PLC raised its stake in shares of Certara, Inc. (NASDAQ:CERT) by 198.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 70,525 shares of the company’s stock after buying an additional 46,880 shares during the quarter. Barclays PLC’s holdings in Certara were worth $825,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the business. Wasatch Advisors LP lifted its holdings in shares of Certara by 22.4% during the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after purchasing an additional 1,651,076 shares in the last quarter. Geneva Capital Management LLC lifted its holdings in shares of Certara by 0.7% during the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock valued at $64,525,000 after purchasing an additional 37,392 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Certara by 40.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after purchasing an additional 1,128,006 shares in the last quarter. State Street Corp lifted its holdings in shares of Certara by 3.4% during the 3rd quarter. State Street Corp now owns 3,679,699 shares of the company’s stock valued at $43,089,000 after purchasing an additional 122,411 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Certara by 9.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after purchasing an additional 273,095 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CERT. Barclays cut their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Friday, September 27th. Finally, Robert W. Baird cut their target price on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Certara presently has a consensus rating of “Hold” and an average price target of $15.92.

Certara Trading Up 11.4 %

NASDAQ CERT opened at $11.96 on Thursday. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of -59.80, a PEG ratio of 5.86 and a beta of 1.52. The stock’s 50 day moving average price is $10.86 and its two-hundred day moving average price is $11.95. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.87.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter in the prior year, the business posted $0.06 EPS. The business’s revenue was up 10.7% compared to the same quarter last year. As a group, analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.